Systemic sclerosis pulmonary – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 19 Aug 2026 04:04:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Systemic sclerosis pulmonary – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of CC-97540 (CD19‑Targeted NEX‑T CAR T) versus drug combination in adults with active systemic sclerosis https://clinicaltrials.eu/trial/phase-3-study-of-cd19-targeted-nex-t-car-t-cc-97540-versus-drug-combination-to-assess-efficacy-and-safety-in-adults-with-active-systemic-sclerosis/ Mon, 03 Aug 2026 10:45:34 +0000 https://clinicaltrials.eu/trial/phase-3-study-of-cd19-targeted-nex-t-car-t-cc-97540-versus-drug-combination-to-assess-efficacy-and-safety-in-adults-with-active-systemic-sclerosis/ The study focuses on adults with active Systemic Sclerosis, a condition that causes the skin and internal organs to become thick and stiff, often accompanied by Interstitial Lung Disease, a lung problem that makes breathing difficult because of scarring. The experimental therapy being tested combines BMS-986353 with CD19-targeted NEX-T CAR T Cells, a type of cell‑based treatment designed to target specific immune cells. Participants may also receive standard medicines that are commonly used for this disease, including nintedanib, fludarabine phosphate, tocilizumab, cyclophosphamide, and rituximab.

The purpose of the study is to compare how well the new cell‑based therapy works against these standard medicines in improving lung function. Participants are randomly assigned to receive either the experimental treatment or the usual care, and both groups are observed over several months to see changes in breathing ability and skin condition.

During the study, lung capacity is measured using Forced Vital Capacity, which records the amount of air a person can blow out after a deep breath. Participants visit the clinic at regular intervals for safety checks, blood tests, and simple examinations of skin thickness. The overall follow‑up period lasts about a year, allowing researchers to track how the disease progresses or improves.

]]> Tulisokibart in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-tulisokibart-in-patients-with-systemic-sclerosis-associated-with-interstitial-lung-disease/ Mon, 03 Aug 2026 10:44:33 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-tulisokibart-in-patients-with-systemic-sclerosis-associated-with-interstitial-lung-disease/ This clinical trial is studying Systemic Sclerosis Associated with Interstitial Lung Disease, a condition in which the immune system causes hardening of the skin and can also lead to scarring in the lungs. The treatment being tested is tulisokibart (also called MK-7240/PRA023), given by vein as an infusion. The purpose of the study is to see how safe this medicine is and whether it may help people with this lung disease. Some participants will receive tulisokibart and others will receive placebo.

The study is planned to last about 50 weeks for each person. During the study, treatment is given at regular times, and health checks are done over the course of the trial to watch for side effects and other changes in health. The study also looks at lung function, which means how well the lungs move air in and out.

]]> Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis https://clinicaltrials.eu/trial/study-on-the-effects-of-rituximab-and-mycophenolate-mofetil-in-patients-with-interstitial-lung-disease-from-systemic-sclerosis/ Mon, 03 Aug 2026 10:27:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-rituximab-and-mycophenolate-mofetil-in-patients-with-interstitial-lung-disease-from-systemic-sclerosis/ This study focuses on Interstitial Lung Disease related to systemic sclerosis, a condition where lung tissue becomes scarred and breathing becomes difficult. The study will test a combination of two medications: rituximab and mycophenolate mofetil. The purpose is to evaluate how well this combination treatment works on lung function compared to using mycophenolate mofetil with a placebo.

The treatment involves receiving rituximab through intravenous infusions, while mycophenolate mofetil is taken by mouth. Some participants will receive rituximab with mycophenolate mofetil, while others will receive a placebo with mycophenolate mofetil. Sodium chloride solution will be used for the intravenous administration of medications.

The study will last 48 weeks, during which participants’ lung function will be monitored. Throughout the study, various tests will be performed to check breathing capacity and overall health status. The treatment involves taking mycophenolate mofetil daily and receiving rituximab or placebo at specific times during the study period.

]]> Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/study-on-vixarelimab-for-patients-with-idiopathic-pulmonary-fibrosis-and-systemic-sclerosis-associated-interstitial-lung-disease/ Mon, 03 Aug 2026 10:12:33 +0000 https://clinicaltrials.eu/trial/study-on-vixarelimab-for-patients-with-idiopathic-pulmonary-fibrosis-and-systemic-sclerosis-associated-interstitial-lung-disease/ This clinical trial is focused on studying two lung-related diseases: Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. The treatment being tested is called Vixarelimab, which is given as a solution for injection. The study will compare the effects of Vixarelimab with a placebo to understand its impact on lung function in patients with these conditions.

The purpose of the study is to evaluate how well Vixarelimab works in improving lung function. Participants will receive either Vixarelimab or a placebo through subcutaneous injection, which means the injection is given under the skin. The study will last for a period of up to 104 weeks, during which various health assessments will be conducted to monitor changes in lung function and overall health.

Throughout the study, participants will undergo regular check-ups to measure changes in their lung capacity and other health indicators. The study aims to provide valuable information on the safety and effectiveness of Vixarelimab in treating these lung diseases, potentially leading to better treatment options in the future.

]]>